×
About 7,086 results

ALLMedicine™ Narcolepsy Center

Research & Reviews  2,931 results

Pitolisant (Wakix) for narcolepsy.
https://www.ncbi.nlm.nih.gov/pubmed/33647004
The Medical Letter on Drugs and Therapeutics;

Mar 1st, 2021 - Pitolisant (Wakix) for narcolepsy.|2021||

Reliability and validity of the Chinese version of Narcolepsy Severity Scale in adult p...
https://doi.org/10.1016/j.sleep.2021.02.008
Sleep Medicine; Li C, Spruyt K et. al.

Feb 28th, 2021 - To evaluate reliability and validity of the Chinese version of Narcolepsy Severity Scale (NSS) in adult patients with narcolepsy type 1 (NT1). One hundred and fifty-one adult patients (≥18 years) with NT1 were recruited. All filled out the 15-item...

Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults.
https://doi.org/10.1016/j.clinthera.2021.01.017
Clinical Therapeutics; Seiden D, Tyler C et. al.

Feb 26th, 2021 - FT218 is an investigational, once-nightly, modified-release formulation of sodium oxybate (SO). SO effectively treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. Current approved SO formulations, at effective doses of 6...

Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long s...
https://doi.org/10.1016/j.sleep.2021.01.018
Sleep Medicine; Inoue Y, Tabata T et. al.

Feb 25th, 2021 - Few treatments are available for patients with idiopathic hypersomnia (IH). Modafinil, an established treatment for narcolepsy, was tested for efficacy and safety in Japanese patients with IH without long sleep time. This multicenter, randomized, ...

Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
https://doi.org/10.1093/sleep/zsab043
Sleep Kaushik MK, Aritake K et. al.

Feb 20th, 2021 - Orexins/hypocretins are hypothalamic neuropeptides that promote and stabilize wakefulness by binding to the orexin receptor type-1 (OX1R) and type-2 (OX2R). Disruption of orexinergic signaling results in the sleep disorder narcolepsy in mice, rats...

see more →

Guidelines  9 results

Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-us-fda-approval-sunositm

Mar 19th, 2019 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstr...

Practice Parameters for the Respiratory Indications for Polysomnography in Children
https://j2vjt3dnbra3ps7ll1clb4q2-wpengine.netdna-ssl.com/wp-content/uploads/2017/07/pppolysomnographychildren.pdf
R. Nisha Aurora

Nov 30th, 2010 - Assessment for sleep disorders in children has long relied on a comprehensive history and physical exam. In certain conditions, most commonly sleep related breathing disorders (SRBD), polysomnography (PSG) was performed as an adjunctive tool to ai.

EFNS guidelines on disease-specific CSF investigations.
https://www.ncbi.nlm.nih.gov/pubmed/19475759
European Journal of Neurology; Deisenhammer F, Egg R et. al.

May 28th, 2009 - We reviewed the literature for disease-specific markers in cerebrospinal fluid (CSF) and evaluated their diagnostic and prognostic relevance in neurological diseases. High tau protein in combination with low amyloid beta levels has a high sensitiv...

Practice parameters for the treatment of narcolepsy and other hypersomnias of central o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276123
Sleep Morgenthaler TI, Kapur VK et. al.

Feb 5th, 2008 - These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hyp...

WAKIX® (pitolisant) tablets
https://www.wakix.com

WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy

see more →

Drugs  381 results see all →

Clinicaltrials.gov  3,489 results

Pitolisant (Wakix) for narcolepsy.
https://www.ncbi.nlm.nih.gov/pubmed/33647004
The Medical Letter on Drugs and Therapeutics;

Mar 1st, 2021 - Pitolisant (Wakix) for narcolepsy.|2021||

Reliability and validity of the Chinese version of Narcolepsy Severity Scale in adult p...
https://doi.org/10.1016/j.sleep.2021.02.008
Sleep Medicine; Li C, Spruyt K et. al.

Feb 28th, 2021 - To evaluate reliability and validity of the Chinese version of Narcolepsy Severity Scale (NSS) in adult patients with narcolepsy type 1 (NT1). One hundred and fifty-one adult patients (≥18 years) with NT1 were recruited. All filled out the 15-item...

Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults.
https://doi.org/10.1016/j.clinthera.2021.01.017
Clinical Therapeutics; Seiden D, Tyler C et. al.

Feb 26th, 2021 - FT218 is an investigational, once-nightly, modified-release formulation of sodium oxybate (SO). SO effectively treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. Current approved SO formulations, at effective doses of 6...

Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long s...
https://doi.org/10.1016/j.sleep.2021.01.018
Sleep Medicine; Inoue Y, Tabata T et. al.

Feb 25th, 2021 - Few treatments are available for patients with idiopathic hypersomnia (IH). Modafinil, an established treatment for narcolepsy, was tested for efficacy and safety in Japanese patients with IH without long sleep time. This multicenter, randomized, ...

Xywav - (calcium, magnesium, potassium, and sodium oxybates) solution-Jazz Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e0ae43a-037f-42af-8e23-a0e51d75abe8

Feb 22nd, 2021 - XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. XYWAV is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytim...

see more →

News  253 results

MHRA Issues Safety Update on Modafinil and Congenital Malformations
https://www.medscape.com/viewarticle/941265

Nov 18th, 2020 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update on the potential risk of congenital malformations with the use of the narcolepsy drug modafinil during pregnancy. The update follows a European review o...

Rapid Weight Gain in an Excessively Sleepy Girl With Asthma
https://reference.medscape.com/viewarticle/938423_3

Oct 8th, 2020 - Discussion This case is very challenging because the patient had the findings of and met the criteria for OSA, periodic limb movement disorder (PLMD)/restless legs syndrome (RLS), and hypersomnolence. She also had several historical findings that ...

Solriamfetol Effective for Treating Excessive Daytime Sleepiness
https://www.medscape.com/viewarticle/938654

Oct 6th, 2020 - NEW YORK (Reuters Health) - The selective norepinephrine-dopamine-reuptake inhibitor solriamfetol is well-tolerated and effective for treating excessive daytime sleepiness (EDS) in patients with narcolepsy or obstructive sleep apnea (OSA), accordi...

Fast Five Quiz: Sleep Disorders
https://reference.medscape.com/viewarticle/934767_1

Aug 2nd, 2020 - Difficulty with sleep is common, with some studies showing as many as 1 in 3 individuals report some type of sleep disorder. Reduced sleep duration has been linked to almost half of the 15 leading causes of death in the United States. From poor pe...

Fast Five Quiz: Sleep Disorders
https://reference.medscape.com/viewarticle/934767_6

Aug 2nd, 2020 - Answer 5/5 Which of the following is most accurate regarding narcolepsy? Your peers chose: Confirmation of hypocretin excess is one of the diagnostic criteria for narcolepsy 0% According to the AASM, narcolepsy type 1 requires the absence of type ...

see more →

Patient Education  23 results see all →